Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immucell ( (ICCC) ) has shared an update.
On August 20, 2025, ImmuCell Corporation extended its $1 million line of credit with Maine Community Bank through September 11, 2026, with interest at the National Prime Rate. This extension provides ImmuCell with continued financial flexibility, potentially impacting its operational capabilities and market positioning positively.
The most recent analyst rating on (ICCC) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Immucell stock, see the ICCC Stock Forecast page.
Spark’s Take on ICCC Stock
According to Spark, TipRanks’ AI Analyst, ICCC is a Neutral.
Immucell’s overall stock score is driven by mixed financial performance and technical indicators suggesting potential bearish momentum. Strong sales growth and margin improvements from the earnings call are positive, but concerns about future sales and regulatory delays weigh on the outlook. The valuation indicates the stock is relatively expensive, with no dividend yield to attract income-focused investors.
To see Spark’s full report on ICCC stock, click here.
More about Immucell
Average Trading Volume: 23,331
Technical Sentiment Signal: Buy
Current Market Cap: $55.12M
For a thorough assessment of ICCC stock, go to TipRanks’ Stock Analysis page.